Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Huapont Taps US Partner To Ride China Precision Medicine Wave

Executive Summary

2016 is the year for precision medicine therapies to be included in China’s National Major Project for Innovation. Looking to seize market opportunity in the newly funded area, Huapont Life Sciences has linked up with and invested in a US bioventure partner for a gene therapy for refractory angina.

You may also be interested in...



China’s ICT Looks To Build On Promising CAR-T Results

Chinese biotech Innovative Cellular Therapeutics has reported promising results for its CAR-T cell immunotherapy in a small leukemia study, and the company is now planning to expand its clinical program into new indications including solid tumors, and to explore global markets.

CARsgen Seizes China Precision Medicine Opportunity, Looks Globally

Amid China’s big push into precision medicine, the Chinese bioventure CARsgen is developing what it says is the world’s first CAR-T cell immunotherapy for liver cancer and is seeking a global partner to develop its proprietary therapies. The company is also aiming to raise additional funding to advance its pipeline.

China Powers Into Precision Medicine

Metastatic tumors, diabetes, cardiovascular and rare diseases are among the areas being targeted in China’s new precision medicine initiative, in a bet that could be worth $10 billion by 2030.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC100339

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel